CN101822767B - External plaster for treating sclerotin and osseous nerve diseases - Google Patents
External plaster for treating sclerotin and osseous nerve diseases Download PDFInfo
- Publication number
- CN101822767B CN101822767B CN2009100213859A CN200910021385A CN101822767B CN 101822767 B CN101822767 B CN 101822767B CN 2009100213859 A CN2009100213859 A CN 2009100213859A CN 200910021385 A CN200910021385 A CN 200910021385A CN 101822767 B CN101822767 B CN 101822767B
- Authority
- CN
- China
- Prior art keywords
- sclerotin
- external plaster
- osseous
- blood
- plaster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 25
- 201000010099 disease Diseases 0.000 title claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 21
- 108010048734 sclerotin Proteins 0.000 title claims abstract description 16
- 210000005036 nerve Anatomy 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 11
- 230000001537 neural effect Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 21
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 210000003205 muscle Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 230000036407 pain Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000008736 traumatic injury Effects 0.000 abstract description 3
- 241000545744 Hirudinea Species 0.000 abstract description 2
- 206010003246 arthritis Diseases 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000864411 Alangium platanifolium Species 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 241000051984 Blepharidachne Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 241000223782 Ciliophora Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 abstract 1
- LWNOIQJAJMHMSM-UHFFFAOYSA-N Pariphyllin Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1OC2C(C(O)C(CO)O2)O)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O LWNOIQJAJMHMSM-UHFFFAOYSA-N 0.000 abstract 1
- 240000004824 Trimezia steyermarkii Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 16
- 241000237903 Hirudo Species 0.000 description 9
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 7
- 241000131808 Scolopendra Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000009286 sanguis draxonis Substances 0.000 description 5
- 241001489978 Eupolyphaga Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 4
- 229960002179 ephedrine Drugs 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- -1 monomethyl ephedrine Chemical compound 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- 102000007625 Hirudins Human genes 0.000 description 3
- 108010007267 Hirudins Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 206010005963 Bone formation increased Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- NJICGAVMYWKCMW-GWJXCKMPSA-N Dipterocarpol Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4CC[C@@H]3[C@]21C NJICGAVMYWKCMW-GWJXCKMPSA-N 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N trans-caryophyllene Natural products C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NJICGAVMYWKCMW-UHFFFAOYSA-N 20 R-Hydroxydammarenon Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4CCC3C21C NJICGAVMYWKCMW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SYTRJRUSWMMZLV-UHFFFAOYSA-N 4-epimatricin Natural products C1=CC(O)(C)C2C1=C(C)CC(OC(C)=O)C1C2OC(=O)C1C SYTRJRUSWMMZLV-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- NFHFNBFYZIJLKZ-UHFFFAOYSA-N Asarinin Natural products CC1(OCC2C1COC2c3ccc4OCOc4c3)c5ccc6OCOc6c5 NFHFNBFYZIJLKZ-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- UFJPCTSKTPSJTK-UHFFFAOYSA-N Dryobalanone Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC(C(O)(CO)CCC=C(C)C)C4CCC3C21C UFJPCTSKTPSJTK-UHFFFAOYSA-N 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- QNGQIURXCUHNAT-UHFFFAOYSA-N Eucarvone Chemical compound CC1=CC=CC(C)(C)CC1=O QNGQIURXCUHNAT-UHFFFAOYSA-N 0.000 description 1
- OPQCAZJRIRHZQK-UHFFFAOYSA-N Eucarvone Natural products CC1=CC=CCC(C)(C)C1=O OPQCAZJRIRHZQK-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000777488 Heteractis magnifica DELTA-stichotoxin-Hmg2b Proteins 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- SYTRJRUSWMMZLV-AHWDLOTJSA-N Matricin Natural products O=C(O[C@@H]1[C@H]2[C@H](C)C(=O)O[C@@H]2[C@H]2[C@](O)(C)C=CC2=C(C)C1)C SYTRJRUSWMMZLV-AHWDLOTJSA-N 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- PSZDOEIIIJFCFE-UHFFFAOYSA-N Oleanolic alcohol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C)(C)CC5C4=CCC3C21C PSZDOEIIIJFCFE-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000255626 Tabanus <genus> Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HRBMESHSNKKVBJ-OLKYXYMISA-N [(1r,4r,5r,7s)-8-benzyl-7-[[4-(dimethylamino)phenyl]carbamoyl]-8-azabicyclo[3.2.1]octan-4-yl] n-ethylcarbamate Chemical compound N1([C@@H]2C[C@@H]([C@H]1CC[C@H]2OC(=O)NCC)C(=O)NC=1C=CC(=CC=1)N(C)C)CC1=CC=CC=C1 HRBMESHSNKKVBJ-OLKYXYMISA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 1
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- PSZDOEIIIJFCFE-OSQDELBUSA-N erythrodiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PSZDOEIIIJFCFE-OSQDELBUSA-N 0.000 description 1
- HTZRWCSRPTWJCT-UHFFFAOYSA-N erythrodiol Natural products CC1(C)CCC2(CO)CCC3C(CCC4C3(C)CCC5C(C)(C)C(O)CCC45C)C2C1 HTZRWCSRPTWJCT-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002192 fatty aldehydes Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
The invention relates to an external plaster for treating sclerotin and osseous nerve diseases, such as lumbar cervical herniated disk, osteoproliferation, waist and keen ache, arthritis, traumatic injury and the like. A special external plaster is prepared according to the therapeutic principles of internal diseases treated by external application and searching for the primary cause of disease in treatment by processing the following pure traditional Chinese medicine raw materials: herba ephedrae, Caulis Spatholobi, ground beeltle, Alangium platanifolium root, leech, centipede, ciliate desert-grass, asarum, borneol, dragon's blood, Pariphyllin, cassia twig and the like as base recipes. The external plaster has the functions of softening sclerotin, relaxing muscles, invigorating the circulation of blood, promoting blood circulation and removing blood stasis, dispersing swelling, diminishing inflammation and relieving pain, has good effect in the aspect of treating the sclerotin and osseous nerve diseases and can obviously reduce the threat and the harm to human health.
Description
Technical field
Content of the present invention belongs to the preparing technical field of pharmaceuticals, relates to a kind of external plaster that can be used for treating sclerotin and the neural class disease of bone.
Background technology
Sclerotin and bone neural class disease such as waist, prolapse of cervical intervertebral disc, hyperosteogeny, slippage, deviate from, the diseases such as waist, knee joint pain, rheumatic arthritis, traumatic injury all bring great misery to the patient.More for the method for above-mentioned disease at medical domain at present, mainly comprise operative treatment and non-operative treatment.Operative treatment because misery is large, be fit to narrow range, postoperatively may leave over the reasons such as sequela and surgery cost height, a lot of people are unwilling to accept.Non-operative treatment mainly refers to interior or topical Drug therapy.External used medicine comprises plaster agent, paste etc., but effect is also not fully up to expectations.And traditional innerlich anwenden therapeutic modality limits to due to route of administration, curative effect is poor, ingredient in the administration process through intestinal juice stomach acids destroy and liver metabolism, often do not reach effective blood drug concentration, affected curative effect of medication, in addition in high amount of drug with also causing other toxic and side effects, impairing the liver, the impairment of the spleen, injure one's stomach.
Summary of the invention
The object of the invention is to the problem that exists for state of the art, by excavating the abundant Chinese medicine resource of motherland, and then provide a kind of prescription science, the external plaster that is used for the treatment of sclerotin and the neural class disease of bone that easy to prepare, curative effect is high.
The preparation scheme of external plaster of the present invention comes from motherland's medical science about traditional determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs thoughts such as " inner disease outer treat ", " treatment must aim at the pathogenesis of disease ", and it is the designer by concentrating on studies for a long time and by the concentrated summary of designer's clinical practice experience for many years, developing acquisition many medicine and pharmacology books and folk remedy at all times.According to the understanding to sclerotin and the neural class disease of bone pathogenesis pathology of medical science at all times, designer of the present invention is take pure Chinese medicine raw material Herba Ephedrae, Caulis Spatholobi, Eupolyphaga Seu Steleophaga, Radix Alangii, Hirudo, Scolopendra, Herba Achilleae, Herba Asari, Borneolum Syntheticum, Sanguis Draxonis, Rhizoma Paridis, Ramulus Cinnamomi etc. as basic recipe, be processed into special-purpose external plaster, this plaster has softening sclerotin clinically, dredge that muscle is invigorated blood circulation, the effect of invigorating blood circulation paralysis, detumescence, anti-inflammatory analgetic,, aspect the treatment to sclerotin and the neural class disease of bone, good effect being arranged, can significantly reduce its threat to health of people and harm.
Each active drug raw material and the weight proportion that form this external plaster are:
In the present invention's prescription, medicinal ingredient and the pharmacological action of each herbal medicine are as described below.
Herba Ephedrae
[composition] Ephedra sinica stem contains alkaloid 1%～2%, and wherein 40%～90% is ephedrine, is secondly the LN monomethyl ephedrine of pseudo-numb ephedrine and trace.
[pharmacology] function relieving the exterior syndrome by diaphoresis, depressed lung-energy dispersing, diuretic.The vasoconstrictor effects of ephedrine is gentleer and lasting, can make coronary vasodilation, increases coronary blood flow.
Caulis Spatholobi
[composition] contains milletol.
The agent of [pharmacology] Caulis Spatholobi raised path between farm fields has significant curative effect to rat oral gavage PARA FORMALDEHYDE PRILLS(91,95) " arthritis ", and decoct or tincture intravenous injection do not make significant difference to breathing, blood pressure and the Bufo siccus lower limb vascular perfusion of anesthetized dog
Eupolyphaga Seu Steleophaga
[composition] main volatile oil, aminoacid, protein, saccharide, fat, steroid, phenols, organic acid and alkaloid etc. of containing, 8 kinds of micro elements needed by human such as another iron content, manganese, zinc, copper.Base volatile oil has identified 20 components, and wherein naphthalene content is the highest, accounts for 22.19%, and various fatty aldehydes and aromatic aldehyde account for 24.95%, and aldehyde may be the stink composition of this product.
[pharmacology] blood coagulation resisting function, eupolyphoge sinensis water extract are given rat oral gavage 7 days continuously, and heavy dose of group and usual amounts group be obvious prolong rats bleeding time and recalcification time all.
Radix Alangii
Fibrous root and the root bark of [composition] Radix Alangii contain alkaloid, phenols, aminoacid, organic acid, resin, and fibrous root mainly contains alkaloid and glucoside, contains cardiotonic glycoside again.
[pharmacology] of flaccid muscles and analgesic activity, the total alkaloids that proposes from the Radix Alangii fibrous root all can cause of flaccid muscles to rabbit, rat, mice and Canis familiaris L..
Hirudo
[composition] Hirudo mainly contains protein.Contain a kind of anticoagulative substance name hirudin in fresh Hirudo saliva.
[pharmacology] hirudin is not heated or the destruction of ethanol, can stop the effect of thrombin to fibronectin, hinders blood coagulation.Hirudo can also secrete a kind of H-subst, thereby expansible blood capillary and increase hemorrhagely, and its alcohol extract has the effect that suppresses blood coagulation, is better than Tabanus, Moschus moschiferous worm, Semen Persicae etc., and the alcohol formulations effect is better than water formulation.20 milligrams of hirudins can stop solidifying of 100 gram human bloods.
Scolopendra
[composition] contains the toxic component of two kinds of similar Venenum apis; be histamine sample material and hemolytic protein; still fatty oil, cholesterol, formic acid etc.; once isolated again oxylysine, aminoacid has histidine, arginine, ornithine, lysine, glycine, alanine, leucine, phenylalanine, serine, taurine, glutamic acid etc.
[pharmacology] antitumor action, the injection of Scolopendra Hirudo can be made the spermatogonium of white mice necrose, disappear, and illustrates tumor cell is had inhibitory action.Experiment in vitro proves: the Scolopendra leech injection is positive to the red rate of dying of cancerous cell, and Scolopendra Hirudo to the suppression ratio to white mice hepatocarcinoma tumor body is 26%, and the reticuloendothelial cell function is had potentiation.
Herba Achilleae
[composition] contains Millefolium element, blue Oleum sesami, Camphora and takes off the acetyl matricin, contains again equisetic acid, inulin and cineole.
[pharmacology] achillea millefolium in vitro has the bacteriostasis of height to staphylococcus aureus, escherichia coli, bacillus pyocyaneus, sonne bacillus, bacterium flexneri.
Herba Asari
[composition] Herba Asari contains volatile oil approximately 3%, and the volatilization main body of oil is methyleugenol (accounting for 50%), also has saishinone, pinene, Eucarvone, safrole, 1, 8-Cineole, stamen asarinin etc.
[pharmacology] local anesthesia effect, magnificent Herba Asari water logging agent or pure preserved material can be blocked the sciatic conduction of impulse of the frog, and Herba Asari volatile oil still has surface anesthetic effect.
Borneolum Syntheticum
[composition] Borneolum Syntheticum is the crystallization that obtains in the resin of Borneolum Syntheticum and volatile oil.Contain multiple ter penoids in the resin of Borneolum Syntheticum and volatile oil, except Borneolum Syntheticum, still contain the triterpenoids such as the sesquiterpenes such as oxalene, beta-elemene, caryophyllene and oleanolic acid, dipterocarpol, dryobalanone, erythrodiol.
[pharmacology] its effect is similar to Camphora, is mainly used in promoting the circulation of QI to relieve pain, at external higher concentration, bacteriostasis is arranged, and can be used for osteoneuralgia or antiinflammatory.
Sanguis Draxonis
[composition] is the mixture of a kind of resin ester and dracoresinotannol.
[pharmacology] antifungic action, Sanguis Draxonis water logging agent (1: 2) are in vitro to the multiple pathogenic inhibitory action that has in various degree such as trichophyton, trichophyton gypseum, oidium schoenleinii.
Rhizoma Paridis
[composition] rhizome contains the multiple Saponins such as 3-glycoside, 3-rhamnose Fructus Vitis viniferae glycoside, 3-rhamnose arabinose glycoside and 3-tetrose glycoside of pariphylin, dioscin, the pre-ruscogenin of potato, also contains tannin and 18 gynaminic acid, kreatinin, alkaloid, yellow intoxicated, sterone, ecdyson, daucosterol etc.
[pharmacology] anti-microbial effect, but treating tumor.100% Rhizoma Paridis preparation all has inhibitory action to dysentery bacterium, Bacillus typhi, Salmonella paratyphi, bacillus enteritidis, escherichia coli, paracolon, bacillus pyocyaneus, staphylococcus aureus, Hemolytic streptococcus, meningococcus, and the inhibitory action of pyococcus is better than Rhizoma Coptidis.
Ramulus Cinnamomi
[composition] contains Ramulus Cinnamomi alcohol etc.
[pharmacology] antibacterial action, the Ramulus Cinnamomi ethanol extract can suppress escherichia coli, bacillus subtilis and staphylococcus aureus external, and Staphylococcus albus, dysentery bacterium, Typhoid and paratyphoid first bacillus, streptococcus pneumoniae, aerobacteria, Bacillus proteus, anthrax bacillus, Salmonella enteritidis, vibrio cholera etc. are also had inhibitory action.
In practical application, the external plaster that is used for the treatment of the neural class disease of sclerotin and bone of the present invention technique is routinely made the external plaster of pharmaceutics record, applies ointment or plaster as medical ointment plaster, medicated powder etc.During use,, first with the heating of this plaster, then the medicated powder face is affixed on patient's sore place or the grain corresponding with disease and the place at acupuncture point, reaches the effect of the neural class disease of effective treatment sclerotin and bone.Generally, sticking once sustainable 5～7 days can go and exchange cards containing all personal details and become sworn brothers again.Should be noted: as after sticking plaster, patient's skin has the reaction of itching, and this place's skin is smeared and is got final product with the Rhizoma Zingiberis Recens wiping or with the clear ointment of skin; The anemia of pregnant woman prohibits subsides in addition, if any indivedual anaphylaxis persons, does not also use.
In development process of the present invention, be therapeutic effect and the safety that proves this external plaster, the designer had once carried out the experimental study of clinicing aspect with regard to this plaster, and the patient that 102 examples are accepted diagnosis and treatment has been carried out visiting statistics, and result is as described below.
One, tcm diagnosis: lumbar vertebra point dish is outstanding, hyperosteogeny, slippage, lumbocrural pain, rheumatic arthritis, traumatic injury etc.
Two, Therapeutic Method: be affixed on patient's diseased region after thermoplastic, changed once in every 5～7 days, every 30～35 days is a course for the treatment of.
Three, efficacy assessment standard: with reference to " partially new tcm clinical practice choosing " and " Surgery of Chinese Medicine ", be divided into recovery from illness, produce effects, effective, invalid four kinds.
1. recovery from illness: diseased region transference cure General Symptoms disappears;
2. produce effects: the diseased region symptom is obviously improved and is reached 70% above part and General Symptoms disappears substantially;
3. effective: diseased region passs on 30%～70% well;
4. invalid: diseased region improves less than 30%, and part and whole body are without improvement.
Four, therapeutic outcome: for many years clinical, hundreds of remaining routine patients obtain curative effect.
Show by the clinical research to 102 routine patients, Chinese medicine external of the present invention pastes, and to tested treatment case total effective rate, is 100%, 98 examples of wherein fully recovering, effective 2 examples, produce effects 1 example, invalid 1 example.Clinical observation demonstrates fully this plaster and has the effects such as thin muscle is invigorated blood circulation, anti-inflammatory analgetic, putrefaction removing and tissue regeneration promoting, the cold expelling that stimulates the menstrual flow, and easy to use, safe.
The specific embodiment
Embodiment one:
Get respectively Herba Ephedrae 80g, Caulis Spatholobi 150g, Eupolyphaga Seu Steleophaga 120g, Radix Alangii 70g, Hirudo 80g, Scolopendra 50g, Herba Achilleae 80g processed, Herba Asari 60g, Borneolum Syntheticum 70g, Sanguis Draxonis 120g, Rhizoma Paridis 180g, Ramulus Cinnamomi 150g, with above-mentioned active drug raw material routinely preparation technology make the coating unguentum, be on the Medical paster material of 8～10cm with the above-mentioned coating unguentum polylith diameter that is laid in respectively, every drug of topical application amount is 8～12g, and with this, makes the external plaster that is used for the treatment of sclerotin and the neural class disease of bone of the present invention.
Embodiment two:
Get respectively Herba Ephedrae 100g, Caulis Spatholobi 130g, Eupolyphaga Seu Steleophaga 130g, Radix Alangii 75g, Hirudo 80g, Scolopendra 55g, Herba Achilleae 90g processed, Herba Asari 70g, Borneolum Syntheticum 75g, Sanguis Draxonis 120g, Rhizoma Paridis 175g, Ramulus Cinnamomi 150g, with above-mentioned active drug raw material routinely preparation technology make powder, above-mentioned powder is set in respectively in the penetrating cotton Medical paster material processed that the polylith diameter is 8～10cm, establishing dose in every is 8～12g, and with this, makes the external plaster that is used for the treatment of sclerotin and the neural class disease of bone of the present invention.
Claims (1)
1. external plaster that is used for the treatment of the neural class disease of sclerotin and bone is characterized in that it is by the active drug raw material of the following weight proportion external plaster made of technique routinely:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100213859A CN101822767B (en) | 2009-03-05 | 2009-03-05 | External plaster for treating sclerotin and osseous nerve diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100213859A CN101822767B (en) | 2009-03-05 | 2009-03-05 | External plaster for treating sclerotin and osseous nerve diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101822767A CN101822767A (en) | 2010-09-08 |
| CN101822767B true CN101822767B (en) | 2013-11-20 |
Family
ID=42687072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100213859A Expired - Fee Related CN101822767B (en) | 2009-03-05 | 2009-03-05 | External plaster for treating sclerotin and osseous nerve diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101822767B (en) |
-
2009
- 2009-03-05 CN CN2009100213859A patent/CN101822767B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 刘华新等,1.试述腰椎间盘突出症从肝论治.《四川中医》.2008,第26卷(第12期),34-36. |
| 南京中医药大学.八角枫根、一枝嵩、蚤休.《中药大辞典》.2006,34、6、2448. * |
| 试述腰椎间盘突出症从肝论治;刘华新等,1;《四川中医》;20081215;第26卷(第12期);34-36 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101822767A (en) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169928B (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN102205026B (en) | Chinese medicinal composition for treating children chronic sinusitis and preparation method thereof | |
| CN101658331B (en) | Chinese medicinal herb adhering corsage for preventing and treating mammary diseases | |
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| CN101518600B (en) | Chinese medicinal composition for treating bacterial or fungal dermatosis and preparation method thereof | |
| EP3821902B1 (en) | Traditional chinese medicine composition, traditional chinese medicine compound preparation and preparation method and use thereof | |
| CN103463297A (en) | Traditional Chinese medicine composition for treating eczema of scrotum as well as preparation method and use thereof | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN104258278A (en) | Gushangling (for bone injury) spray | |
| CN113209238A (en) | Lotion for treating hand-foot syndrome caused by targeted medicament and preparation method thereof | |
| CN100387291C (en) | Medicine for treating pulmonary tuberculosis | |
| CN110141622B (en) | Traditional Chinese medicine composition for treating pain and preparation method and application thereof | |
| CN101822767B (en) | External plaster for treating sclerotin and osseous nerve diseases | |
| CN111920883A (en) | External preparation for treating herpes zoster and preparation method thereof | |
| CN111991527A (en) | Foot medicated bath formula and preparation process thereof | |
| CN105232888A (en) | Traditional Chinese medicine combination for treating itchy skin after hemodialysis | |
| CN105031380A (en) | Drug for oral local anesthesia of pregnant woman and preparation method thereof | |
| CN104887970A (en) | Acupuncture and moxibustion physiotherapy ointment for external use | |
| CN110585379A (en) | External application medicine for treating dermatitis | |
| CN111870628B (en) | Medicine for treating chronic hepatitis B | |
| CN110141621B (en) | Traditional Chinese medicine composition for treating pain and preparation method and application thereof | |
| CN111084842B (en) | External traditional Chinese medicine composition for treating scapulohumeral periarthritis, cervical spondylosis, lumbar disc herniation and osteoarthritis | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN116870072A (en) | Traditional Chinese medicine composition, application, gel and preparation method of gel | |
| Chen | Herbology in Three Traditional Medicines for Acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131120 |